BIM-23027 

BIM-23027 is a selective agonist of sst₂ receptor (EC₅₀=0.32 nM), with similar effect to somatostatin (SRIF), a cyclic tetradecapeptide. BIM-23027 stimulates dopamine release, which is mediated by a Glu-dependent mechanism^[1][2].

EC50: 0.32 nM (sst₂)^[2]

BIM-23027 (10, 50, and 100 nM; 90 min) significantly increases the level of dopamine^[1].
BIM-23027 (50 nM; 15 min prior to SRIF (100 nM)) significantly attenuates the actions of the naturally-occurring peptide^[1].
BIM-23027 (30 nM; 30 min) carbachol-stimulated increases in basal SCC by 60-70%, with an EC₅₀ value of 0.29 nM^[2].
BIM-23027 interacts with a sub-population of [125I]Tyr11-SRIF binding sites in rat colonic mucosal membranes^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

794.94

C₄₃H₅₄N₈O₇

78981-49-4

Cyclo[{(NMe)Ala}-FWKTF]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hathway GJ, et al. Evidence that somatostatin sst2 receptors mediate striatal dopamine release. Br J Pharmacol. 1999 Nov;128(6):1346-52.  [Content Brief]

  [2]. McKeen ES, et al. Somatostatin receptors mediating inhibition of basal and stimulated electrogenic ion transport in rat isolated distal colonic mucosa. Naunyn Schmiedebergs Arch Pharmacol. 1995 Oct;352(4):402-11.  [Content Brief]